Lidocaine for dinutuximab‐associated pain? A multicenter retrospective observational cohort study-Reference-Cited by-同舟云学术

Lidocaine for dinutuximab‐associated pain? A multicenter retrospective observational cohort study

Published:2022-04-20 Issue:9 Volume:69 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Featherly Julianna¹²^ORCID,Baxter Wojnowicz Sarabeth¹²,Steidl Kelly¹²^ORCID,Burgess Jeni¹²^ORCID

Affiliation:

1. Upstate University Hospital Syracuse New York

2. Upstate Golisano Children's Hospital Syracuse New York

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29653

Reference11 articles.

1. YuAL GilmanA.Phase III randomized study of chimeric antibody 14.18 (Ch14.18) in high‐risk neuroblastoma following myeloablative therapy and autologous stem cell rescue. Children's Oncology Group ANBL0032.

2. Dinutuximab.In: Lexi‐Drugs. Lexi‐Comp Inc. Updated September 2021. Accessed June2021.

3. Intravenous Lidocaine

4. Lidocaine (Systemic).In: Lexi‐Drugs. Lexi‐Comp Inc. Updated June 2021. Accessed June2021.

5. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma;2024-05-28

2. The Pharmacological Treatment of Neuropathic Pain in Children;Current Neuropharmacology;2024-01

3. Pain mitigation and management strategies for anti‐GD2 infusions: An expert consensus;Pediatric Blood & Cancer;2023-02-11